This trial is evaluating whether Empagliflozin 10 MG will improve 1 primary outcome and 4 secondary outcomes in patients with Ascites. Measurement will happen over the course of Baseline to 12 weeks.
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. Empagliflozin 10 MG is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Ascites can be caused by either intra-abdominal or pleural fluid shifts. A high level of protein in the ascites, serum total protein >30g/dl, is indicative of more advanced ascites. If the ascites contain high levels of albumin, neovenous fluid can be assumed to be due to portal vein thrombosis, while low levels with low albumin or protein-rich ascites is indicative of malignancy; both ascites and retro-peritoneal fluid can be sampled for protein analysis. In all, protein levels should be evaluated in ascites." - Anonymous Online Contributor
"The presence of blood, mucus or protein, together with symptoms of pain or fatigue should raise the possibility of an ascites. However, a diagnostic fluid study (serum total and differential protein, urea) is required to rule out fluid overload." - Anonymous Online Contributor
"There is no cure for ascites and symptom control is the focus of treatment. Patients suffering from ascites should therefore be advised to get involved in active exercise, a low-fat diet and regular exercise for optimal symptom control." - Anonymous Online Contributor
"The number of people with ascites may be increasing. This may be a result of people with chronic liver disease having a higher risk of developing ascites." - Anonymous Online Contributor
"Causes of ascites can be classified into infectious and noninfectious diseases. Infectious causes are more frequently found in children. In patients with acute liver failure, viral serology can help identify the cause of ascites and help guide therapy; however, other causes of ascites must be considered in patients with chronic liver failure. Clinicians could be more proactive in investigating ascites in patients who are critically unwell because initial investigations can lead to an urgent diagnosis and therapy, especially in children." - Anonymous Online Contributor
"Bacterial infections, particularly pneumonia, or ascitic fluid is frequently diagnosed only when ascites is found in association with medical problems or in those with poor performance status. Treatment for ascites is usually directed at the underlying cause. Antibiotics and antimalaria medication will be taken only in patients with persistent or recurrent symptoms and ascites despite adequate medical treatments." - Anonymous Online Contributor
"EMPA (10 mg) plus MET were as effective as MET alone in terms of reducing mean SBP, DBP, and DBP. Neither EMPA 10 mg nor MET alone decreased 24-hour urinary albumin excretion (UAE). It appears like the mechanism of action of EMPA and EMPA/MET are to reduce blood pressure rather than to change albumin excretion. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535991/)." - Anonymous Online Contributor
"Empagliflozin may be an effective adjunct for treating patients with cirrhosis and portal hypertension associated with refractory ascites; however, further clinical studies are needed in patients with decompensated ascites." - Anonymous Online Contributor
"Empagliflozin, compared with placebo, was well tolerated by patients with ascites; empagliflozin improved key domains of quality of life and reduced the impact of ascites on health-related quality of life." - Anonymous Online Contributor
"Empagliflozin 10 mg was well tolerated by patients with type 2 diabetes inadequately controlled on the initial prescription and achieved similar HbA1c reductions to those previously reported for once-daily dosing of empagliflozin 10 and/or 5 mg." - Anonymous Online Contributor
"There are no clear indications which individuals should consider clinical trials for ascites from their medical or paramedical history. There are however specific criteria which must be met." - Anonymous Online Contributor
"Recent findings of this pilot study reveal substantial safety concerns regarding empagliflozin therapy. The use of weight-adjusted doses of empagliflozin had no significant impact on side effects. It was hypothesized that the lack of empagliflozin impact on weight is due to its potent blood pressure lowering effects." - Anonymous Online Contributor